within Pharmacolibrary.Drugs.ATC.A;

model A16AX16
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.586,
    Cl             = 3.0 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 2.5 / 1000000,
    adminCount     = 1,
    Vd             = 0.011300000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Givosiran is a small interfering RNA (siRNA) therapeutic aimed at the treatment of acute hepatic porphyrias (AHP). It reduces the production of aminolevulinic acid synthase 1 (ALAS1) in the liver, thereby lowering toxic heme intermediates. It is approved and marketed under the brand name Givlaari.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic profile in adults with acute hepatic porphyria following subcutaneous administration.</p><h4>References</h4><ol><li><p>McDougall, R, et al., &amp; Wu, JT (2022). The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of . <i>Drug metabolism and disposition: the biological fate of chemicals</i> 50(6) 781–797. DOI:<a href=&quot;https://doi.org/10.1124/dmd.121.000428&quot;>10.1124/dmd.121.000428</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34154993/&quot;>https://pubmed.ncbi.nlm.nih.gov/34154993</a></p></li><li><p>Jeon, JY, et al., &amp; Mitra, A (2022). Pharmacokinetic and Pharmacodynamic Modeling of siRNA Therapeutics - a Minireview. <i>Pharmaceutical research</i> 39(8) 1749–1759. DOI:<a href=&quot;https://doi.org/10.1007/s11095-022-03333-8&quot;>10.1007/s11095-022-03333-8</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35819583/&quot;>https://pubmed.ncbi.nlm.nih.gov/35819583</a></p></li><li><p>Li, J, et al., &amp; Chong, S (2021). Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved . <i>Drug metabolism and disposition: the biological fate of chemicals</i> 49(7) 572–580. DOI:<a href=&quot;https://doi.org/10.1124/dmd.121.000381&quot;>10.1124/dmd.121.000381</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33941543/&quot;>https://pubmed.ncbi.nlm.nih.gov/33941543</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A16AX16;
